ProCE Banner Activity

EMBER-3: Imlunestrant ± Abemaciclib vs SoC ET in Patients With ER+/HER2- ABC After Progression on Prior ET

Conference Coverage
Slideset

The phase III EMBER-3 trial reported significant improvement in median PFS with imlunestrant vs SoC endocrine therapy in patients with ESR1-mutated ER+/HER- advanced breast cancer and with imlunestrant plus abemaciclib vs imlunestrant alone in patients with ER+/HER- advanced breast cancer regardless of ESR1 mutation status.

Released: December 13, 2024

Expiration: June 12, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation